Interaction of bone morphogenetic proteins with cells of the osteoclast lineage: review of the existing evidence

[1]  Tomislav Smoljanovic,et al.  Bone morphogenetic protein. , 2009, Journal of neurosurgery. Spine.

[2]  Scott Saunders,et al.  Bone Density Ligand, Sclerostin, Directly Interacts With LRP5 but Not LRP5G171V to Modulate Wnt Activity , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  H. Miyaji,et al.  Dentin resorption and cementum-like tissue formation by bone morphogenetic protein application. , 2006, Journal of periodontal research.

[4]  Sherry L. Werner,et al.  Concerted Action of Smad and CREB-binding Protein Regulates Bone Morphogenetic Protein-2-stimulated Osteoblastic Colony-stimulating Factor-1 Expression* , 2006, Journal of Biological Chemistry.

[5]  H. Yoshikawa,et al.  Bone Morphogenetic Proteins in Bone Stimulate Osteoclasts and Osteoblasts During Bone Development , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  K. Takaoka,et al.  Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand. , 2006, Endocrinology.

[7]  R. Delamarter,et al.  Graft Resorption With the Use of Bone Morphogenetic Protein: Lessons From Anterior Lumbar Interbody Fusion Using Femoral Ring Allografts and Recombinant Human Bone Morphogenetic Protein-2 , 2006, Spine.

[8]  G. Roodman.  Regulation of Osteoclast Differentiation , 2006, Annals of the New York Academy of Sciences.

[9]  R. Sasso,et al.  Resorptive Response of rhBMP2 Simulating Infection in an Anterior Lumbar Interbody Fusion With a Femoral Ring , 2006, Journal of spinal disorders & techniques.

[10]  E. Schwarz,et al.  Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. , 2006, Bone.

[11]  C. Wan,et al.  Osteoclastogenesis in the nonadherent cell population of human bone marrow is inhibited by rhBMP‐2 alone or together with rhVEGF , 2006, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[12]  W. Harris,et al.  Tsukushi controls ectodermal patterning and neural crest specification in Xenopus by direct regulation of BMP4 and X-delta-1 activity , 2006, Development.

[13]  Thomas A Einhorn,et al.  Recombinant human bone morphogenetic proteins in the treatment of fractures. , 2005, Foot and ankle clinics.

[14]  Eleftherios Tsiridis,et al.  Current concepts of molecular aspects of bone healing. , 2005, Injury.

[15]  N. Amanat,et al.  Manipulation of the Anabolic and Catabolic Responses With OP‐1 and Zoledronic Acid in a Rat Critical Defect Model , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  P. Giannoudis,et al.  Application of recombinant BMP-7 on persistent upper and lower limb non-unions. , 2005, Injury.

[17]  J. Reeve,et al.  Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  S. Yao,et al.  Chronology and regulation of gene expression of RANKL in the rat dental follicle. , 2005, European journal of oral sciences.

[19]  M. Kawanami,et al.  Formation and resolution of ankylosis under application of recombinant human bone morphogenetic protein-2 (rhBMP-2) to class III furcation defects in cats. , 2005, Journal of periodontal research.

[20]  H. Yoshikawa,et al.  The role of bone morphogenetic proteins in endochondral bone formation. , 2005, Cytokine & growth factor reviews.

[21]  M. Yanagita.  BMP antagonists: their roles in development and involvement in pathophysiology. , 2005, Cytokine & growth factor reviews.

[22]  F. Bakker,et al.  Bone morphogenetic proteins. Development and clinical efficacy in the treatment of fractures and bone defects. , 2005, The Journal of bone and joint surgery. American volume.

[23]  Benjamin M. Wu,et al.  Bone morphogenetic protein 2 and retinoic acid accelerate in vivo bone formation, osteoclast recruitment, and bone turnover. , 2005, Tissue engineering.

[24]  P. Giannoudis,et al.  Application of bone morphogenetic proteins in orthopaedic practice: their efficacy and side effects , 2005, Expert opinion on drug safety.

[25]  Di Chen,et al.  Bone Morphogenetic Proteins , 2004, Growth factors.

[26]  S. Yao,et al.  Regulation of secretion of osteoprotegerin in rat dental follicle cells. , 2004, European journal of oral sciences.

[27]  Yoshihisa Suzuki,et al.  Prolonged ectopic calcification induced by BMP-2-derived synthetic peptide. , 2004, Journal of biomedical materials research. Part A.

[28]  R. Behringer,et al.  Bone Morphogenetic Protein Type IA Receptor Signaling Regulates Postnatal Osteoblast Function and Bone Remodeling* , 2004, Journal of Biological Chemistry.

[29]  M. Karperien,et al.  Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist , 2004, The Journal of experimental medicine.

[30]  R. Jung,et al.  Effect of rhBMP-2 on guided bone regeneration in humans. , 2003, Clinical oral implants research.

[31]  H. Ozawa,et al.  Osteoclast differentiation in ectopic bone formation induced by recombinant human bone morphogenetic protein 2 (rhBMP-2) , 2003, Journal of Bone and Mineral Metabolism.

[32]  T. Einhorn.  Clinical applications of recombinant human BMPs: early experience and future development. , 2003, The Journal of bone and joint surgery. American volume.

[33]  Nobuyuki Itoh,et al.  Sclerostin Is a Novel Secreted Osteoclast-derived Bone Morphogenetic Protein Antagonist with Unique Ligand Specificity* , 2003, Journal of Biological Chemistry.

[34]  H. Hagiwara,et al.  Treatment of Myoblastic C2C12 Cells with BMP-2 Stimulates Vitamin D-induced Formation of Osteoclasts , 2003, Calcified Tissue International.

[35]  A. Economides,et al.  0163-769X/03/$20.00/0 Endocrine Reviews 24(2):218–235 Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/er.2002-0023 Bone Morphogenetic Proteins, Their Antagonists, and the Skeleton , 2022 .

[36]  P. Aspenberg,et al.  A combination of bisphosphonate and BMP additives in impacted bone allografts , 2003, Acta orthopaedica Scandinavica.

[37]  S. Santavirta,et al.  Recombinant Human Bone Morphogenetic Protein-2 for Treatment of Open Tibial Fractures: A Prospective, Controlled, Randomized Study of Four Hundred and Fifty Patients , 2002, The Journal of bone and joint surgery. American volume.

[38]  J. Lane,et al.  Safety Profile for the Clinical Use of Bone Morphogenetic Proteins in the Spine , 2002, Spine.

[39]  Jay R Lieberman,et al.  The role of growth factors in the repair of bone. Biology and clinical applications. , 2002, The Journal of bone and joint surgery. American volume.

[40]  S D Cook,et al.  The use of osteogenic protein-1 in reconstructive surgery of the hip. , 2001, The Journal of arthroplasty.

[41]  T. Suda,et al.  Bifurcation of osteoclasts and dendritic cells from common progenitors. , 2001, Blood.

[42]  N. Ueno,et al.  Bone Morphogenetic Protein 2 Stimulates Osteoclast Differentiation and Survival Supported by Receptor Activator of Nuclear Factor-κB Ligand. , 2001, Endocrinology.

[43]  T. Einhorn,et al.  Bone Regeneration: New Findings and Potential Clinical Applications , 2001, The Journal of the American Academy of Orthopaedic Surgeons.

[44]  G. Roodman,et al.  ADAM8: A Novel Osteoclast Stimulating Factor , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[45]  G. Zych,et al.  Osteogenic Protein-1 (Bone Morphogenetic Protein-7) in the Treatment of Tibial Nonunions: A Prospective, Randomized Clinical Trial Comparing rhOP-1 with Fresh Bone Autograft* , 2001, The Journal of bone and joint surgery. American volume.

[46]  H. Anderson,et al.  Bone Morphogenetic Protein (BMP) Localization in Developing Human and Rat Growth Plate, Metaphysis, Epiphysis, and Articular Cartilage , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[47]  M. Kumegawa,et al.  Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. , 2000, Bone.

[48]  J. Massagué,et al.  Transcriptional control by the TGF‐β/Smad signaling system , 2000 .

[49]  R. Jilka,et al.  Essential Requirement of BMPs‐2/4 for Both Osteoblast and Osteoclast Formation in Murine Bone Marrow Cultures from Adult Mice: Antagonism by Noggin , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[50]  W. Dougall,et al.  RANK is essential for osteoclast and lymph node development. , 1999, Genes & development.

[51]  S. Cook.  Preclinical and clinical evaluation of osteogenic protein-1 (BMP-7) in bony sites. , 1999, Orthopedics.

[52]  S. Bulstra,et al.  Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. , 1999, The Journal of bone and joint surgery. British volume.

[53]  T. Martin,et al.  Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. , 1999, Endocrine reviews.

[54]  K. Yamato,et al.  Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1alpha through upregulation of osteoclast differentiation factor and cyclooxygenase-2. , 1999, Biochemical and biophysical research communications.

[55]  K. Kusumoto,et al.  Comparison of recombinant and purified human bone morphogenetic protein. , 1999, The British journal of oral & maxillofacial surgery.

[56]  B. Riggs,et al.  Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. , 1998, Biochemical and biophysical research communications.

[57]  P. ten Dijke,et al.  Distinct and overlapping patterns of localization of bone morphogenetic protein (BMP) family members and a BMP type II receptor during fracture healing in rats. , 1998, Bone.

[58]  T. Sakou.  Bone morphogenetic proteins: from basic studies to clinical approaches. , 1998, Bone.

[59]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[60]  S. Vukicevic,et al.  Bone Morphogenetic Protein-7 (Osteogenic Protein-1, OP-1) and Tooth Development , 1998, Journal of dental research.

[61]  D J Simmons,et al.  The origin of bone formed by heterotopic periosteal autografts. , 1997, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[62]  R. Derynck,et al.  TGF-beta receptor signaling. , 1997, Biochimica et biophysica acta.

[63]  R. Coutts,et al.  Instructional Course Lectures, The American Academy of Orthopaedic Surgeons - Growth Factors as Therapeutic Agents*† , 1996 .

[64]  J. Massagué.  TGFβ Signaling: Receptors, Transducers, and Mad Proteins , 1996, Cell.

[65]  K. Chihara,et al.  Stimulatory effect of bone morphogenetic protein‐2 on osteoclast‐like cell formation and bone‐resorbing activity , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[66]  P. Lehenkari,et al.  Effects of recombinant human osteogenic protein-1 on the differentiation of osteoclast-like cells and bone resorption. , 1995, Biochemical and biophysical research communications.

[67]  R. Jilka,et al.  Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. , 1995, The New England journal of medicine.

[68]  C. Haipek,et al.  Cloning and identification of annexin II as an autocrine/paracrine factor that increases osteoclast formation and bone resorption. , 1994, The Journal of biological chemistry.

[69]  K. Takaoka,et al.  [Bone remodelling and its regulators]. , 1994, Nihon rinsho. Japanese journal of clinical medicine.

[70]  O. Vuolteenaho,et al.  Osteoclast recruiting activity in bone matrix. , 1994, Bone and mineral.

[71]  K. Takaoka,et al.  Transient and localized expression of bone morphogenetic protein 4 messenger RNA during fracture healing , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[72]  V. Paralkar,et al.  Osteogenin and recombinant bone morphogenetic protein 2B are chemotactic for human monocytes and stimulate transforming growth factor beta 1 mRNA expression. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[73]  Y. Takada,et al.  A simple method to assess osteoclast-mediated bone resorption using unfractionated bone cells. , 1992, Bone and mineral.

[74]  V. Rosen,et al.  Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro , 1991, The Journal of cell biology.

[75]  D. Huhn,et al.  Analysis of CD34-positive hemopoietic progenitor cells from normal human adult peripheral blood: flow-cytometrical studies and in-vitro colony (CFU-GM, BFU-E) assays , 1991, Annals of Hematology.

[76]  E. Drier,et al.  OP‐1 cDNA encodes an osteogenic protein in the TGF‐beta family. , 1990, The EMBO journal.

[77]  V. Rosen,et al.  Recombinant human bone morphogenetic protein induces bone formation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[78]  G. Hattersley,et al.  Calcitonin receptors as markers for osteoclastic differentiation: correlation between generation of bone-resorptive cells and cells that express calcitonin receptors in mouse bone marrow cultures. , 1989, Endocrinology.

[79]  V. Rosen,et al.  Novel regulators of bone formation: molecular clones and activities. , 1988, Science.

[80]  V. Rosen,et al.  Purification and characterization of other distinct bone-inducing factors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[81]  K. Takagi,et al.  Effect of bone marrow mononuclear phagocytes on the bone matrix-induced bone formation in rats. , 1987, Clinical orthopaedics and related research.

[82]  P. Sexton,et al.  Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. , 1986, The Journal of clinical investigation.

[83]  A. Boskey,et al.  Bone structure, composition, and mineralization. , 1984, The Orthopedic clinics of North America.

[84]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[85]  M. Urist,et al.  Bone: Formation by Autoinduction , 1965, Science.

[86]  M C Sogayar,et al.  Bone morphogenetic proteins: from structure to clinical use. , 2005, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[87]  F. Watzinger,et al.  Bone morphogenetic proteins 5 and 6 stimulate osteoclast generation. , 2005, Journal of biomedical materials research. Part A.

[88]  N. Udagawa.  Mechanisms involved in bone resorption , 2004, Biogerontology.

[89]  N. Haas,et al.  Differences in the Fusion and Resorption Activity of Human Osteoclasts After Stimulation with Different Growth Factors Released From a Polylactide Carrier , 2004, Calcified Tissue International.

[90]  S. Ahmed,et al.  Biology and clinical applications , 2004 .

[91]  Kozo Nakamura,et al.  Signal transduction pathways regulating osteoclast differentiation and function , 2003, Journal of Bone and Mineral Metabolism.

[92]  J. Szatkowski,et al.  Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). , 2003, The Journal of bone and joint surgery. American volume.

[93]  K. Yamato,et al.  Role of TGF-beta family in osteoclastogenesis induced by RANKL. , 2002, Cellular signalling.

[94]  Wong Rk,et al.  Bone induction in clinical orthodontics: a review. , 2002 .

[95]  K. Yamato,et al.  Role of TGF-β family in osteoclastogenesis induced by RANKL , 2002 .

[96]  A. Rabie,et al.  Bone induction in clinical orthodontics: a review. , 2002, The International journal of adult orthodontics and orthognathic surgery.

[97]  N. Ueno,et al.  Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand. , 2001, Endocrinology.

[98]  C. Lohse,et al.  Treatment of peri-implant defects with combination growth factor cement. , 2000, Journal of periodontology.

[99]  B. Olsen,et al.  Bone development. , 2000, Annual review of cell and developmental biology.

[100]  M. Laursen,et al.  Recombinant bone morphogenetic protein-7 as an intracorporal bone growth stimulator in unstable thoracolumbar burst fractures in humans: preliminary results , 1999, European Spine Journal.

[101]  T. Einhorn,et al.  Growth factor treatment of fractures. , 1997, Instructional course lectures.

[102]  E. Jimi,et al.  Role of 1 alpha,25-dihydroxyvitamin D3 in osteoclast differentiation and function. , 1997, Methods in enzymology.

[103]  R. Coutts,et al.  Growth factors as therapeutic agents. , 1997, Instructional course lectures.

[104]  J. Massagué.  TGFbeta signaling: receptors, transducers, and Mad proteins. , 1996, Cell.

[105]  S. Manolagas.  Bone marrow, cytokines, and bone remodeling , 1995 .

[106]  A. Wyllie,et al.  Cell death: the significance of apoptosis. , 1980, International review of cytology.